{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:18:00Z","timestamp":1792001880427,"version":"4.4.0"},"reference-count":30,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"27","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2021,9,20]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Donafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative, has shown efficacy in phase Ia and Ib hepatocellular carcinoma (HCC) studies. This study compared the efficacy and safety of donafenib versus sorafenib as first-line therapy for advanced HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>This open-label, randomized, parallel-controlled, multicenter phase II-III trial enrolled patients with unresectable or metastatic HCC, a Child-Pugh score \u2264 7, and no prior systemic therapy from 37 sites across China. Patients were randomly assigned (1:1) to receive oral donafenib (0.2 g) or sorafenib (0.4 g) twice daily until intolerable toxicity or disease progression. The primary end point was overall survival (OS), tested for noninferiority and superiority. Efficacy was primarily assessed in the full analysis set (FAS), and safety was assessed in all treated patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Between March 21, 2016, and April 16, 2018, 668 patients (intention-to-treat) were randomly assigned to donafenib and sorafenib treatment arms; the FAS included 328 and 331 patients, respectively. Median OS was significantly longer with donafenib than sorafenib treatment (FAS; 12.1 v 10.3 months; hazard ratio, 0.831; 95% CI, 0.699 to 0.988; P = .0245); donafenib also exhibited superior OS outcomes versus sorafenib in the intention-to-treat population. The median progression-free survival was 3.7 v 3.6 months ( P = .0570). The objective response rate was 4.6% v 2.7% ( P = .2448), and the disease control rate was 30.8% v 28.7% (FAS; P = .5532). Drug-related grade \u2265 3 adverse events occurred in significantly fewer patients receiving donafenib than sorafenib (125 [38%] v 165 [50%]; P = .0018).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Donafenib showed superiority over sorafenib in improving OS and has favorable safety and tolerability in Chinese patients with advanced HCC, showing promise as a potential first-line monotherapy for these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.21.00163","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T15:59:35Z","timestamp":1624982375000},"page":"3002-3011","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":376,"title":["Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial"],"prefix":"10.1200","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2289-1521","authenticated-orcid":false,"given":"Shukui","family":"Qin","sequence":"first","affiliation":[{"name":"Cancer Centre of Bayi Hospital, Nanjing Chinese Medicine University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0527-5105","authenticated-orcid":false,"given":"Feng","family":"Bi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanzhi","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Hunan Cancer Hospital of Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Second Hospital of Anhui Medical University, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zishu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieer","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Abdominal Oncology, Zhejiang Cancer Hospital, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinying","family":"Lu","sequence":"additional","affiliation":[{"name":"Liver Cancer Centre, The Fifth Medical Centre of PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Meng","sequence":"additional","affiliation":[{"name":"Minimally Invasive Therapy Centre, Fudan University Shanghai Cancer Centre, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Sixth Medical Centre of PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tangdu Hospital, Air Force Medical University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8691-1232","authenticated-orcid":false,"given":"Xi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, The 900th Hospital of PLA Joint Service Support Force, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aibing","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Nantong Tumor Hospital, Nantong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxu","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhu","sequence":"additional","affiliation":[{"name":"Institute of Cancer, Xinqiao Hospital, Army Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Xin","sequence":"additional","affiliation":[{"name":"Department of Hepatology, The Sixth People's Hospital of Shenyang, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jufeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlu","family":"Shan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Daping Hospital, Army Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhui","family":"Chen","sequence":"additional","affiliation":[{"name":"Intervention and Cell Therapy Centre, Peking University Shenzhen Hospital, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, General Hospital of Northern Theater Command, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4405-1048","authenticated-orcid":false,"given":"Li","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Sun Yat-sen University Cancer Centre, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2109-1557","authenticated-orcid":false,"given":"Xiaoyu","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary and Pancreatic Disease, The First Hospital of Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"You","sequence":"additional","affiliation":[{"name":"Department of Tumor Intervention Therapy, Heping Branch, General Hospital of Northern Theater Command, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenggang","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Cancer Centre of Bayi Hospital, Nanjing Chinese Medicine University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqing","family":"Wu","sequence":"additional","affiliation":[{"name":"Suzhou Zelgen Biopharmaceuticals Co, Ltd, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Public Health, Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21338"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2010.100"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2013.14.12.7251"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0186-y"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.5643"},{"key":"b8","volume-title":"Guidelines for the Diagnosis and Treatment of Primary Liver Cancer","author":"Chinese Society of Clinical Oncology (CSCO)","year":"2020","edition":"2020"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-020-04031-1"},{"key":"b10","volume-title":"Investor Update","author":"Roche","year":"2020"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.3298"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70285-7"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.8372"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4410"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.01.028"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz394.029"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.7746"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.9651"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.e15682"},{"key":"b22","first-page":"10","volume":"1","author":"Qin S","year":"2012","journal-title":"Chin Clin Oncol"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24199"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0179-x"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018797110"},{"key":"b27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1349-7006.2007.00648.x","volume":"99","author":"Furuse J","year":"2008","journal-title":"Cancer Sci"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.00837.x"},{"key":"b29","volume-title":"Center for Drug Evaluation and Research Approval Package for: Application Number NDA 21-923; Clinical Pharmacology and Biopharmaceutics Review","author":"US Food and Drug Administration","year":"2005"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i36.4152"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.21.00163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T19:01:58Z","timestamp":1725303718000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.21.00163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,20]]},"references-count":30,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2021,9,20]]}},"alternative-id":["10.1200\/JCO.21.00163"],"URL":"https:\/\/doi.org\/10.1200\/jco.21.00163","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,20]]},"assertion":[{"value":"2021-01-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}